Monitor the May 11 conference call for any safety or efficacy signals from the first three GBM patients. Positive interim data could provide a near-term catalyst, but given the tiny sample size and early stage, any price move is likely speculative and short-lived.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $1.02entry
- T+1 · 6mo ago 0.00%α −0.23% · $1.02
- T+5 · 6mo ago 0.00%α −1.46% · $1.02
- T+20 · 5mo ago 0.00%α −0.02% · $1.02
- T+60 · 3mo ago +223.53%α +218.69% · $3.30
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau Medical Ltd. filed a 6-K on May 8, 2026, announcing a conference call to discuss interim clinical data from the first three patients treated in its REGAIN trial for recurrent glioblastoma. The filing is a routine update on early-stage clinical progress with no financial data or material corporate events disclosed.
Key Facts
- Conference call scheduled for May 11, 2026 at 8:30am ET to discuss interim data from first three patients in REGAIN trial.
- REGAIN trial is a U.S. study for recurrent glioblastoma not amenable to surgical resection, expected to enroll up to ten patients.
- No financial results, guidance, or material agreements were disclosed in the filing.
Financial Impact
No financial figures reported; pre-revenue clinical-stage company.
Risk Factors
- Interim data from only three patients is not statistically meaningful and may not predict final trial results.
- Alpha Tau has no approved products and relies on future funding; the 20-F notes significant losses and need for additional capital.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-053597 |
| Document: ea028978302ex99-1.htm | 0001213900-26-053597 |
| Document: 0001213900-26-053597-index-headers.html | 0001213900-26-053597 |
| Document: 0001213900-26-053597-index.html | 0001213900-26-053597 |
| Document: 0001213900-26-053597.txt | 0001213900-26-053597 |
Track record
14 reports on DRTSW
9 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 9 of 9 went positive at some point.
Filters
- Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
- Jun 1, 202624w ago 6-K Bullish 7/10 Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
- May 18, 202626w ago 6-K Neutral 5/10 Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
- May 11, 202627w ago 6-K Bullish 7/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 11, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 8, 202627w ago 6-K Neutral 3/10 Viewing Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 8, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 7, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
- May 5, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
- May 4, 202628w ago 6-K Bullish 7/10 Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers